KMKea Martin

Kea Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kea Martin has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells

    by Philipp Müller, Kea Martin, Sebastian Theurich, Jens Schreiner, Spasenija Savic, Grzegorz Terszowski, Didier Lardinois, Viola A. Heinzelmann-Schwarz, Max Schlaak, Hans-Michael Kvasnicka, et al.

  • Open Access

    Supplementary Figures 1 - 9, Table 1 from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells

    by Philipp Müller, Kea Martin, Sebastian Theurich, Jens Schreiner, Spasenija Savic, Grzegorz Terszowski, Didier Lardinois, Viola A. Heinzelmann-Schwarz, Max Schlaak, Hans-Michael Kvasnicka, et al.

  • Open Access

    Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy

    by Pascal Hänggi, Butrint Aliu, Kea Martin, Ruben Herrendorff, Andreas Johann Steck

    Background and Objectives The objective of the retrospective analysis was to test the hypothesis that changes in serum anti-myelin-associated glycoprotein (MAG) autoantibodies are associated with clinical response to immunotherapy in patients with anti-MAG neuropathy. Methods As of January 29, 2020, we used anti-myelin-associated glycoprotein-related search strings in the Medline database to identify studies that provided information on anti-MAG immunoglobulin M (IgM) autoantibodies and clinical outcomes during immunotherapies. The relative change in anti-MAG IgM titers, paraprotein levels, or total IgM was determined before, during, or posttreatment, and the patients were assigned to “responder,” “nonresponder,”’ or “acute deteriorating” category depending on their clinical response to treatment. The studies were qualified as “supportive” or “not supportive” depending on the percentage of patients exhibiting an association between relative change of anti-MAG antibody titers or levels and change in clinical outcomes. Results Fifty studies with 410 patients with anti-MAG neuropathy were included in the analysis. Forty studies with 303 patients supported the hypothesis that a “responder” patient had a relative reduction of anti-MAG antibody titers or levels that is associated with clinical improvements and “nonresponder” patients exhibited no significant change in anti-MAG IgM antibodies. Six studies with 93 patients partly supported, and 4 studies with 26 patients did not support the hypothesis. Discussion The retrospective analysis confirmed the hypothesis that a relative reduction in serum anti-MAG IgM antibodies is associated with a clinical response to immunotherapies; a sustained reduction of at least 50% compared with pretreatment titers or levels could be a valuable indicator for therapeutic response.


  • Open Access

    Immune cell landscaping reveals a protective role for regulatory T cells during kidney injury and fibrosis

    by Fernanda Do Valle Duraes, Armelle Lafont, Martin Beibel, Kea Martin, Katy Darribat, Rachel Cuttat, Annick Waldt, Ulrike Naumann, Grazyna Wieczorek, Swann Gaulis, et al.

    Acute kidney injury (AKI) and chronic kidney diseases are associated with high mortality and morbidity. Although the underlying mechanisms determining the transition from acute to chronic injury are not completely understood, immune-mediated processes are critical in renal injury. We have performed a comparison of 2 mouse models leading to either kidney regeneration or fibrosis. Using global gene expression profiling we could identify immune-related pathways accounting for the majority of the observed transcriptional changes during fibrosis. Unbiased examination of the immune cell composition, using single-cell RNA sequencing, revealed major changes in tissue-resident macrophages and T cells. Following injury, there was a marked increase in tissue-resident IL-33R + and IL-2Ra + regulatory T cells (Tregs). Expansion of this population before injury protected the kidney from injury and fibrosis. Transcriptional profiling of Tregs showed a differential upregulation of regenerative and proangiogenic pathways during regeneration, whereas in the fibrotic environment they expressed markers of hyperactivation and fibrosis. Our data point to a hitherto underappreciated plasticity in Treg function within the same tissue, dictated by environmental cues. Overall, we provide a detailed cellular and molecular characterization of the immunological changes during kidney injury, regeneration, and fibrosis.


  • Requirement of Mucosa‐Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor–Induced Arthritis, but Not Fcγ Receptor–Mediated Platelet Elimination, in Mice

    by Kea Martin, Ratiba Touil, Grozdan Cvijetic, Laura Israel, Yeter Kolb, Sophie Sarret, Stéphanie Valeaux, Elena Degl'INnocenti, Thomas Le Meur, Nadja Caesar, et al.

    Objective: Fcγ receptors (FcγR) play important roles in both protective and pathogenic immune responses. The assembly of the CBM signalosome encompassing caspase recruitment domain–containing protein 9, B cell CLL/lymphoma 10, and mucosa‐associated lymphoid tissue lymphoma translocation protein 1 (MALT‐1) is required for optimal FcγR‐induced canonical NF‐κB activation and proinflammatory cytokine release. This study was undertaken to clarify the relevance of MALT‐1 protease activity in FcγR‐driven events and evaluate the therapeutic potential of selective MALT‐1 protease inhibitors in FcγR‐mediated diseases.Methods: Using genetic and pharmacologic disruption of MALT‐1 scaffolding and enzymatic activity, we assessed the relevance of MALT‐1 function in murine and human primary myeloid cells upon stimulation with immune complexes (ICs) and in murine models of autoantibody‐driven arthritis and immune thrombocytopenic purpura (ITP).Results: MALT‐1 protease function is essential for optimal FcγR‐induced production of proinflammatory cytokines by various murine and human myeloid cells stimulated with ICs. In contrast, MALT‐1 protease inhibition did not affect the Syk‐dependent, FcγR‐mediated production of reactive oxygen species or leukotriene B4. Notably, pharmacologic MALT‐1 protease inhibition in vivo reduced joint inflammation in the murine K/BxN serum–induced arthritis model (mean area under the curve for paw swelling of 45.42% versus 100% in control mice; P = 0.0007) but did not affect platelet depletion in a passive model of ITP.Conclusion: Our findings indicate a specific contribution of MALT‐1 protease activity to FcγR‐mediated events and suggest that MALT‐1 protease inhibitors have therapeutic potential in a subset of FcγR‐driven inflammatory disorders.


  • Open Access

    Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell–Mediated Autoimmunity

    by Kea Martin, Ratiba Touil, Yeter Kolb, Grozdan Cvijetic, Kiichi Murakami, Laura Israel, Fernanda Duraes, David Buffet, Anton Glück, Satoru Niwa, et al.

    The paracaspase Malt1 is a key regulator of canonical NF-κB activation downstream of multiple receptors in both immune and nonimmune cells. Genetic disruption of Malt1 protease function in mice and MALT1 mutations in humans results in reduced regulatory T cells and a progressive multiorgan inflammatory pathology. In this study, we evaluated the altered immune homeostasis and autoimmune disease in Malt1 protease-deficient (Malt1PD) mice and the Ags driving disease manifestations. Our data indicate that B cell activation and IgG1/IgE production is triggered by microbial and dietary Ags preferentially in lymphoid organs draining mucosal barriers, likely as a result of dysregulated mucosal immune homeostasis. Conversely, the disease was driven by a polyclonal T cell population directed against self-antigens. Characterization of the Malt1PD T cell compartment revealed expansion of T effector memory cells and concomitant loss of a CD4+ T cell population that phenotypically resembles anergic T cells. Therefore, we propose that the compromised regulatory T cell compartment in Malt1PD animals prevents the efficient maintenance of anergy and supports the progressive expansion of pathogenic, IFN-γ–producing T cells. Overall, our data revealed a crucial role of the Malt1 protease for the maintenance of intestinal and systemic immune homeostasis, which might provide insights into the mechanisms underlying IPEX-related diseases associated with mutations in MALT1. Key Points Autoreactive T cells drive the lethal disease in Malt1PD mice. Malt1PD mice display B cell hyperactivation to environmental Ags. IPEX-like disease occurs in Malt1PD mice despite in vitro Treg suppressive activity.


  • Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade

    by Philipp Müller, Matthias Kreuzaler, Tarik Khan, Daniela S. Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Nitz, Oleg Gluz, et al.

    Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT trial) and in a HER2-expressing orthotopic tumor model. In the latter, despite primary resistance to immunotherapy, combined treatment with T-DM1 and anti–CTLA-4/PD-1 (cytotoxic T lymphocyte–associated protein-4/programmed cell death protein-1) was curative because it triggered innate and adaptive immunity. Tumor rejection was accompanied by massive T cell infiltration, TH1 (T helper 1) cell polarization, and, notably, a substantial increase in regulatory T cells. Depletion of regulatory T cells resulted in inflammation and tissue damage, implying their essential role in protecting the host during therapy. This study provides insights into the mechanisms of T-DM1’s therapeutic activity and a rationale for potential therapeutic combination strategies with immunotherapy.


  • Open Access

    Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs

    by Kea Martin, Jens Schreiner, Alfred Zippelius

    Professional antigen-presenting cells, such as dendritic cells are central to the initiation and regulation of anti-cancer immunity. However, in the immunosuppressive environment within a tumor APCs may antagonize anti-tumor immunity by inducing regulatory T cells (Tregs) or anergy of effector T cells due to lack of efficient costimulation. Hence, in an optimal setting, anti-cancer drugs have the power to reduce tumor size and thereby, may induce the release of tumor antigens and, at the same time, modulate APC function towards efficient priming of antigen-specific effector T cells. Selected cytotoxic agents may revert APC dysfunction either by directly maturing DCs or through induction of immunogenic tumor cell death. Furthermore, specific cytotoxic agents may support adaptive immunity by selectively depleting regulatory subsets such as Tregs or myeloid-derived suppressor cells. Perspectively, this will allow developing effective combination strategies with novel immunotherapies to exert complementary pressure on tumors via direct toxicity as well as immune activation. We here review our current knowledge on the capacity of anti-cancer drugs to modulate APC functions to promote durable anti-cancer immune responses.


  • Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity

    by Philipp Müller, Kea Martin, Sebastian Theurich, Michael von Bergwelt-Baildon, Alfred Zippelius

    Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.


  • Open Access

    Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells

    by Philipp Müller, Kea Martin, Sebastian Theurich, Jens Schreiner, Spasenija Savic, Grzegorz Terszowski, Didier Lardinois, Viola A. Heinzelmann-Schwarz, Max Schlaak, Hans-Michael Kvasnicka, et al.

    Antibody–drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30+ malignancies. We hypothesized that its sustained clinical responses could be related to the stimulation of an anticancer immune response. In this study, we demonstrate that the dolastatin family of microtubule inhibitors, from which the cytotoxic component of brentuximab vedotin is derived, comprises potent inducers of phenotypic and functional dendritic cell (DC) maturation. In addition to the direct cytotoxic effect on tumor cells, dolastatins efficiently promoted antigen uptake and migration of tumor-resident DCs to the tumor-draining lymph nodes. Exposure of murine and human DCs to dolastatins significantly increased their capacity to prime T cells. Underlining the requirement of an intact host immune system for the full therapeutic benefit of dolastatins, the antitumor effect was far less pronounced in immunocompromised mice. We observed substantial therapeutic synergies when combining dolastatins with tumor antigen–specific vaccination or blockade of the PD-1–PD-L1 and CTLA-4 coinhibitory pathways. Ultimately, treatment with ADCs using dolastatins induces DC homing and activates cellular antitumor immune responses in patients. Our data reveal a novel mechanism of action for dolastatins and provide a strong rationale for clinical treatment regimens combining dolastatin-based therapies, such as brentuximab vedotin, with immune-based therapies. Cancer Immunol Res; 2(8); 741–55. ©2014 AACR.